New combo aims to boost remission in rare blood cancer
NCT ID NCT04263480
First seen May 14, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This study tests whether adding carfilzomib to ibrutinib works better than ibrutinib alone for people with Waldenström's macroglobulinemia, a rare blood cancer. About 99 participants will receive either the combination or ibrutinib alone. The goal is to see if the combo leads to higher rates of complete or very good partial remission after 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alexandra Hospital
Athens, 11528, Greece
-
Bruederkrankenhaus St. Josef
Paderborn, 33098, Germany
-
Ev. Diakoniekrankenhaus
Bremen, 28239, Germany
-
Gemeinschaftspraxis Mohm / Prange-Krex
Dresden, 01307, Germany
-
Hämatologie/Onkologie München Pasing MVZ GmbH
Munich, 81241, Germany
-
Hämatologisch-Onkologische Schwerpunktpraxis Drs. Schöttker & Pretscher
Würzburg, 97080, Germany
-
Kath. St.-Johannes-Gesellschaft Dortmund gGmbH
Dortmund, 44137, Germany
-
Kliniken Ostalb, Staufenklinikum Schw. Gmuend
Mutlangen, 72557, Germany
-
MediProject Onkologisches Ambulanzzentrum Hannover
Hanover, 30171, Germany
-
Medizinische Universität Wien
Vienna, 1090, Austria
-
OncoResearch Lerchenfeld GmbH
Hamburg, 22081, Germany
-
Praxis Dr. Vehling-Kaiser
Landshut, 84130, Germany
-
Praxis für Hämatologie und Onkologie, onkologische Tagesklinik-VK&K Studien GbR
Landshut, 84036, Germany
-
Uniklinikum Salzburg
Salzburg, 5020, Austria
-
University Hospital Ulm
Ulm, 89081, Germany
-
Universitätsmedizin Rostock
Rostock, 18055, Germany
-
Vivantes Klinikum am Urban
Berlin, 10967, Germany
Conditions
Explore the condition pages connected to this study.